Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (27)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

  2. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

    Haematologica

  3. Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC)

    eClinicalMedicine, Vol. 73

  4. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  5. Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

    HemaSphere

2023

  1. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study

    Journal of Geriatric Oncology, Vol. 14, Núm. 1

  2. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  3. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry

    eClinicalMedicine, Vol. 58

  4. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

  5. Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study

    Cancers, Vol. 15, Núm. 16

2022

  1. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma

    Blood cancer journal, Vol. 12, Núm. 4, pp. 68

  2. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

    Blood, Vol. 140, Núm. 26, pp. 2773-2787

  3. Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

    American Journal of Hematology

2020

  1. Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)

    British Journal of Haematology, Vol. 190, Núm. 6, pp. 854-863

  2. Healthcare reality of the treatment of the high-risk multiple myeloma in Spain

    Medicina Clinica, Vol. 154, Núm. 8, pp. 315-319

  3. Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia

    European Journal of Haematology, Vol. 104, Núm. 3, pp. 259-270

2017

  1. Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice

    International Journal of Hematology, Vol. 106, Núm. 4, pp. 508-516

  2. Further psychometric validation of the GAH scale: Responsiveness and effect size

    Journal of Geriatric Oncology, Vol. 8, Núm. 3, pp. 211-215

  3. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia

    Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9

  4. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice

    British Journal of Haematology, Vol. 178, Núm. 6, pp. 959-970